Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$464.92 USD
-12.98 (-2.72%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $464.91 -0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
VRTX 464.92 -12.98(-2.72%)
Will VRTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRTX
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
Is Most-Watched Stock Vertex Pharmaceuticals Incorporated (VRTX) Worth Betting on Now?
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
Other News for VRTX
Janus Henderson Global Life Sciences Fund Q2 2024 Commentary
Vertex treatment of myotonic dystrophy type 1 granted FDA orphan designation
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Vertex Pharmaceuticals Incorporated (VRTX) Management presents at Cantor Global Healthcare Conference (Transcript)
Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug